By Matt Hicks, COO
The loss of a patent for a branded drug product leads to opportunities for generic-biopharmaceutical manufacturers. Once a blockbuster drug reaches the end of its branded lifecycle, generic manufacturers will gear up to produce lower margin “copies.” However, in the wake of lost market share and declining revenue due to lost patents, many branded biopharmaceutical manufacturers are left with surplus manufacturing equipment. If a branded drug manufacturer has a robust pipeline, such equipment must be removed to make way for the next new product. At the same time, generic manufacturers and contract manufacturing organizations (CMO) are looking for opportunities to lower their costs to win new business with competitive pricing. With a reputable used equipment dealer involved, all of these companies have an opportunity for costs savings.